In the phase 3 EMBRACA trial involving patients with advanced breast cancer and a germline BRCA1/2 mutation, talazoparib monotherapy (oral, 1 mg once daily [QD]) demonstrated significantly longer median progression-free survival compared with standard chemotherapy (8.6 months vs 5.6 months; hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI] 0.41–0.71; P < 0.001) [18]. This evidence concerns the gene BRCA1 and breast cancer.